Muramyl Tripeptide Plus Chemotherapy Reduces Metastasis in Non-Metastatic Osteosarcoma: A Single-Center Experience

Taçyıldız, Nurdan; Ünal, Emel; Dinçaslan, Handan; Cakmak, Hatice Mine; Köse, Kenan; Tanyıldız, Gülşah; Kartal, Özgür

doi:10.31557/apjcp.2020.21.3.715

Cited by 6 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The trial examined the effects of MTP-PE with chemotherapeutic agents, finding that MTP-PE plus a four-drug chemotherapy regimen (doxorubicin, ifosfamide, cisplatin and methotrexate) showed the best event-free survival ( 81 ). Further studies have been done to complement observations from the INT-0133 trial ( 82 ). The use of this NOD2 agonist is approved for youth populations (2 to 30 years of age) as follow-up treatment after surgical removal of the main affected tissue ( 45 ).…”

Section: Discussionmentioning

confidence: 99%

NOD2 activation enhances macrophage Fcγ receptor function and may increase the efficacy of antibody therapy

Merchand-Reyes,

Bull,

Santhanam

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

IntroductionTherapeutic antibodies have become a major strategy to treat oncologic diseases. For chronic lymphocytic leukemia, antibodies against CD20 are used to target and elicit cytotoxic responses against malignant B cells. However, efficacy is often compromised due to a suppressive microenvironment that interferes with cellular immune responses. To overcome this suppression, agonists of pattern recognition receptors have been studied which promote direct cytotoxicity or elicit anti-tumoral immune responses. NOD2 is an intracellular pattern recognition receptor that participates in the detection of peptidoglycan, a key component of bacterial cell walls. This detection then mediates the activation of multiple signaling pathways in myeloid cells. Although several NOD2 agonists are being used worldwide, the potential benefit of these agents in the context of antibody therapy has not been explored.MethodsPrimary cells from healthy-donor volunteers (PBMCs, monocytes) or CLL patients (monocytes) were treated with versus without the NOD2 agonist L18-MDP, then antibody-mediated responses were assessed. In vivo, the Eµ-TCL1 mouse model of CLL was used to test the effects of L18-MDP treatment alone and in combination with anti-CD20 antibody.ResultsTreatment of peripheral blood mononuclear cells with L18-MDP led to activation of monocytes from both healthy donors and CLL patients. In addition, there was an upregulation of activating FcγR in monocytes and a subsequent increase in antibody-mediated phagocytosis. This effect required the NF-κB and p38 signaling pathways. Treatment with L18-MDP plus anti-CD20 antibody in the Eµ-TCL model of CLL led to a significant reduction of CLL load, as well as to phenotypic changes in splenic monocytes and macrophages.ConclusionsTaken together, these results suggest that NOD2 agonists help overturn the suppression of myeloid cells, and may improve the efficacy of antibody therapy for CLL.

show abstract

Section: Discussionmentioning

confidence: 99%

NOD2 activation enhances macrophage Fcγ receptor function and may increase the efficacy of antibody therapy

Merchand-Reyes,

Bull,

Santhanam

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Our results were similar to another study from our country. Taçyıldız et al 22 reported that adding mifamurtide in the high-risk group decreased the probability of distant metastasis, increased the median time to distant metastasis, and improved event-free survival.…”

Section: Discussionmentioning

confidence: 99%

What has changed in the last 25 years in osteosarcoma treatment? A single center experience

et al. 2023

View full text Add to dashboard Cite

Background. Osteosarcoma is the most common type of primary malignant bone tumor in the extremities. The main purpose of this study was to determine clinical features, prognostic factors, and treatment results of patients with osteosarcoma at our center.Methods. We retrospectively analyzed the medical records of children with osteosarcoma between the years 1994-2020.Results. 79 patients were identified (54.4% male, 45.6% female). The most common primary site was the femur (62%). Twenty-six of them (32.9%) had lung metastasis at diagnosis. The patients were treated between 1995-2013 according to the Mayo Pilot II Study protocol, while the others were treated with the EURAMOS protocol between the years 2013-2020. Sixty-nine patients underwent limb salvage surgery as a local treatment, whereas seven underwent amputation. The median follow-up time was 53 months (2.5-265 months). The event-free survival (EFS) and overall survival (OS) rates at 5 years were 52.1% and 61.5%. The 5-year EFS and OS rates were 69.4% and 80% in females; 37.1% and 45.5% in males (p=0.008/p=0.001). The 5-year EFS and OS rates of the patients without metastasis were 63.2% and 66.3%; with metastasis 28.8% and 51.8% (p=0.002/p=0.05). For good-responders, the 5-year EFS and OS rates were 80.2% and 89.1%; while for poor-responders, 35% and 46.7% (p=0.001). Mifamurtide was used in addition to chemotherapy as of the year 2016 (n=16). The 5-year EFS and OS rates were 78.8% and 91.7%, respectively for the mifamurtide group; 55.1% and 45.9%, respectively for the non-mifamurtide group (p=0.015, p=0.027).Conclusions. Metastasis at diagnosis and poor response to preoperative chemotherapy were the most important predictors of survival. Females had a better outcome than males. In our study group, the mifamurtide group's survival rates were significantly higher. Further large studies are needed to validate the efficacy of mifamurtide.

show abstract

“…26 MTP-PE was developed to help prevent lung metastasis in osteosarcoma. 27 Meyers et al and the Pediatric Oncology Group reported that the addition of this agent to the treatment had a positive effect on OS and EFS rates, but the results of the study are controversial due to the simultaneous addition of ifosfamide to the treatment. Moreover, the cost of MTP-PE is very high and beta-glucan is a cost effective and safe dietary supplement without serious side effects.…”

Section: Discussionmentioning

confidence: 99%

Pediatrik sarkom hastalarında profilaktik beta-glukan kullanımının nötropenik ateş sıklığı ve sağkalım üzerine etkisi

Özkan¹,

Küpeli

Çil

et al. 2022

Cukurova Medical Journal

View full text Add to dashboard Cite

Purpose: Some patients with cancer use herbal therapy as an adjunct while receiving conventional cancer treatments. Beta-glucans have direct cytotoxic effects on cancer cells as well as stimulatory effects on the immune system. In this study, a nutritional supplement containing 1,3-1,6 beta-glucan obtained from baker's yeast (Saccharomyces cerevisiae) was used by patients diagnosed with sarcoma, and this study aimed to retrospectively evaluate the effect of beta-glucan use on the incidence of neutropenic fever (NF) and survival rates. Materials and Methods: Among the patients diagnosed with sarcoma between 2014 and 2017, 27 patients who used beta-glucan were included in the beta-glucan group, and 31 patients who did not use beta-glucan were included in the control group. The clinical records of patients were retrospectively analyzed. Results: The number of patients who had NF and the mean length of hospital stay due to NF were higher in the beta-glucan group than those in the control group, but the results were not statistically significant. The overall survival rates at 5 years were 83.3% and 52.9% and event-free survival rates at 5 years were 48.1% and 71% in the beta-glucan and control groups, respectively. Conclusion: The effect of prophylactic beta-glucan use on the incidence of NF and survival rates in pediatric patients with sarcoma should be evaluated more reliably in further prospective studies on a large patient group.

show abstract

Muramyl Tripeptide Plus Chemotherapy Reduces Metastasis in Non-Metastatic Osteosarcoma: A Single-Center Experience

Cited by 6 publications

References 21 publications

NOD2 activation enhances macrophage Fcγ receptor function and may increase the efficacy of antibody therapy

NOD2 activation enhances macrophage Fcγ receptor function and may increase the efficacy of antibody therapy

What has changed in the last 25 years in osteosarcoma treatment? A single center experience

Pediatrik sarkom hastalarında profilaktik beta-glukan kullanımının nötropenik ateş sıklığı ve sağkalım üzerine etkisi

Contact Info

Product

Resources

About